Join this Featured Workgroup!
Elite Investors

This group is for elite investors and traders that are dedicated to participating in an active community that wants to learn from each other, share their research, and work together to do deep analysis of securities. The moderator of this group taught securities analysis at UCLA and is dedicated to helping other investors improve their abilities.

In this private group, membership is restricted and regular contributions are required. Any member not contributing on a regular basis will be removed to make room for a new member.

In your application messsage, please share your background and what you can contribute to the group.



Company Overview and News

0
Dollar dips, stocks slip on Trump remarks

6h theedgemarkets
SYDNEY (July 23): The dollar declined on Monday against major currencies to its lowest in more than two weeks after U.S. President Donald Trump criticised the Federal Reserve's tightening policy, while stocks slipped on fears of further trade protectionist measures.
NAUBF NAB NASXF NABZY

0
US$ dips, stocks slip on Trump remarks

6h thestar.com.my
Trump's comments also hit the greenback, which was last down 0.2 percent at 94.25 against a basket of six major peers, and steepened long-term Treasury yields. "The President's remarks also make it very clear he has a distaste for a stronger dollar, effectively limiting the greenback's ability to perform, at least near term," said Rodrigo Catril, senior forex strategist at National Australia Bank.
NAUBF NAB NASXF NABZY

0
Dollar dips, stocks slip on Trump remarks

7h reuters
SYDNEY (Reuters) - The dollar declined on Monday against major currencies to its lowest in more than two weeks after U.S. President Donald Trump criticized the Federal Reserve’s tightening policy, while stocks slipped on fears of further trade protectionist measures.
NAUBF NAB NASXF NABZY

0
AMP Bank defends mortgage broker commissions

2018-07-22 theage.com.au
AMP Bank warns it would be a "very poor" outcome for home loan customers if changes to mortgage brokers' pay model stopped brokers from pushing rival banks to compete fiercely for customers.
NAUBF NAB NASXF NABZY

0
AMP Bank defends mortgage broker commissions

2018-07-22 smh.com.au
AMP Bank warns it would be a "very poor" outcome for home loan customers if changes to mortgage brokers' pay model stopped brokers from pushing rival banks to compete fiercely for customers.
NAUBF NAB NASXF NABZY

0
Bank bosses face royal commission grilling

2018-07-20 theage.com.au
The bosses of the country's biggest banks are expected to be hauled before the royal commission in November.
NAUBF NAB NASXF NABZY

0
Bank bosses face royal commission grilling

2018-07-20 smh.com.au
The bosses of the country's biggest banks are expected to be hauled before the royal commission in November.
NAUBF NAB NASXF NABZY

0
Not one bank-run super fund makes the 'top 10'

2018-07-19 abc.net.au
Not one bank-run retail superannuation fund has made it into the "top 10" list of funds — whether it be across one or 10 years.
NAUBF NAB NASXF NABZY

0
Sydney Housing Slump Predicted to Last Until at Least 2020

2018-07-18 theedgemarkets
(July 19): Sydney’s property market slump will last at least another two years as tougher lending standards and buyer nerves weigh on prices.
NAUBF NAB NASXF NABZY

0
ANZ backs moratorium on drought-stricken farmers, admits to misconduct

2018-07-17 theage.com.au
ANZ Bank has backed a moratorium on the repossession of drought-stricken farms and, along with the Commonwealth Bank, admitted to "misconduct" in their treatment of some rural customers.
NAUBF NAB NASXF NABZY

0
ANZ backs moratorium on drought-stricken farmers, admits to misconduct

2018-07-17 smh.com.au
ANZ Bank has backed a moratorium on the repossession of drought-stricken farms and, along with the Commonwealth Bank, admitted to "misconduct" in their treatment of some rural customers.
NAUBF NAB NASXF NABZY

0
Passive savers hit as banks slice rates on deposits

2018-07-17 smh.com.au
In the past fortnight, Australia's two biggest banks quietly inflicted a much bigger hit on savings account interest rates than they would dare make to mortgage rates.
NAUBF NAB NASXF NABZY

0
Former Perpetual chief to run MLC ahead of NAB divestment

2018-07-17 theage.com.au
Former Perpetual boss Geoff Lloyd will lead National Australia Bank's MLC business, as the big four bank prepares to split its wealth arm from its core banking operations.
NAUBF NAB NASXF NABZY

0
Former Perpetual chief to run MLC ahead of NAB divestment

2018-07-17 smh.com.au
Former Perpetual boss Geoff Lloyd will lead National Australia Bank's MLC business, as the big four bank prepares to split its wealth arm from its core banking operations.
NAUBF NAB NASXF NABZY

0
These Wheat Prices Are Enough to Put Australia Off Bread - Bloomberg

2018-07-16 bloomberg
Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world.
NAUBF NAB NASXF NABZY

Related Articles

KTOV: Kitov Pharamceuticals Holdings Analysis and Research Report

2018-07-17 - Asif

History and Development of the Company Kitov Pharma was incorporated under the laws of the State of Israel (under a previous name) on August 12, 1968 and its ordinary shares were originally listed for trading on the TASE in 1978. The company's ordinary shares are currently traded on the TASE under the symbol “KTOV”, and its ADSs and its public warrants are traded on NASDAQ under the symbols “KTOV” and “KTOVW”, respectively. In October 2012, the District Court in Lod, Israel approved the creditors arrangement in accordance with Section 350 of the Companies Law in order to effectuate the sale by Kitov Pharma (then known as Mainrom Line Logistics Ltd.) of all its activities, assets, rights, obligations and liabilities to a private company held by its then controlling shareholders, and all rights of Kitov Pharma’s creditors against it were extinguished. The sale was made pursuant to an arrangement between Kitov Pharma and its creditors. Following such sale and a related cash...

ATHX: Athersys Analysis and Research Report

2018-07-17 - Asif

Overview and Recent Developments Athersys is an international biotechnology company that is focused primarily in the field of regenerative medicine. The company's MultiStem® cell therapy, a patented and proprietary allogeneic stem cell product, is its lead platform product and is currently in later-stage clinical development. The company's current clinical development programs are focused on treating neurological conditions, cardiovascular disease, inflammatory and immune disorders, certain pulmonary conditions and other conditions where the current standard of care is limited or inadequate for many patients, particularly in the critical care segment. Current Programs By applying its proprietary MultiStem cell therapy product, the company established therapeutic product development programs treating neurological conditions, cardiovascular disease, inflammatory and immune disorders, and other conditions. The company's programs in the clinical development stage include ...

CYTX: Cytori Therapeutics Analysis and Research Report

2018-07-16 - Asif

General The company's objective is to build a profitable and growing specialty therapeutics company. To meet this objective, Cytori Therapeutics has acquired and are developing two technology platforms that hold promise for treating millions of patients and represent significant potential for increasing shareholder value. The company's current corporate activities fall substantially into advancing these platforms: Cytori Nanomedicine and Cytori Cell Therapy. The Cytori Nanomedicine platform features a versatile liposomal nanoparticle technology for drug encapsulation that has thus far provided the foundation to bring two promising drugs into mid/late stage clinical trials. Nanoparticle encapsulation is promising because it can help improve the delivery and metabolism of many drugs, thus potentially enhancing the therapeutic profile and patient benefits. The company's lead drug candidate, ATI-0918 is a generic version of pegylated liposomal encapsulated doxorubicin. Pegyl...